Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong performance ...

The following is a summary of “Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United ...